Two New Drugs
Berry Pharmaceuticals, LLC, a unique innovative pharmaceutical R&D Texas-based company, is now well positioned to submit two new topical drugs for FDA IND application to the U.S. Food and Drug Administration.
Radiation Dermatitis
There are no FDA drugs approved for this condition.
The first Berry Pharma drug is a topical treatment for the serious disease Acute Cutaneous “Radiation Dermatitis” (RD)
It is being developed to provide topical management for the following cutaneous conditions:
Cancer Treatment
…drug development for topical management of moderate to severe radiation dermatitis following radiotherapy for cancer
Nuclear Exposure
…drug development to treat skin disruption due to nuclear radiation exposure in reactors or nuclear weapon explosion and fallout
Cosmic Radiation
…drug development to treat skin disruption due to prolonged exposure to cosmic radiation for astronauts in outer space travel and habitation
The topical drug was applied on a cancer patient with amazing results
After surgery to remove a tumor near the left tonsil and 33+ radiation treatments, the patient pictured below applied the new topical drug for 10 days. The patient shows severe Radiation Dermatitis which was healed completely with the application of this amazing new topical drug.
BEFORE use of topical drug
The patient’s original reaction was blackened discoloration of the whole radiation damaged neck.
10 days AFTER
The patient’s descriptive wording was “immediate and profound response” to the topical treatment.
“The danger of radiation is always present, whether you’re in orbit, in transit, or on an outer space planetary surface. From mitigation techniques to protection and enclosures, we’re considering this in every environment an astronaut will be in SEPS (space energetic particles).”
The Department of Defense plans to stockpile the FDA-approved cutaneous product in large metropolitan cities for easy access distribution in the event of exposure to a nuclear explosion and nuclear fallout.
Third Degree Burns
It is the first such topical treatment of its kind.
The second Berry Pharma drug is a topical treatment for the critical “Third-Degree (full thickness) Burn Wound” (BN) to address primary burn wound closure without skin grafting in escharotomy (open burn wounds after surgical debridement of devitalized tissue).
The drug in development works in four ways:
Prompts Healing
…autogenous new skin replacement in 12-14 days without skin grafting
Prevents Infection
…natural antibiotic properties reducing burn wound infection
Reduces Pain
…natural analgesia reduces the need for post-escharotomy pain medications
Reduces Scarring
…natural pharmaceutical reduction of burn wound scarring and closed burn scar revision
The topical drug was applied on a patient with a thermal burn
The drug in development was applied on a 70-year-old Caucasian female after a thermal burn with a hot iron. The burn was treated topically with amazing results.
BEFORE
This images the thermal burn scar on day one on the right forearm.
AFTER
This image is of the same right forearm after 60 days of serum BID applications. The scar is healed, atrophy is filled in. There is no infection scar or hypertrophy.
Medical costs for the public for third-degree burn wound care are 10.5 billion USD annually in the USA. Medical expenses for burn scars cost the US public approximately 7.5 billion USD annually in the USA.
This represents a challenge today in Burn Medicine. No known burn treatment has proven efficacy in healing burn escharotomy wounds by the primary intention of autogenously using the body’s cellular tissue to achieve primary burn wound closure.
If you find our story compelling, contact us to partner in furthering our mission to heal people’s diseases through innovative pharmaceutical development.
A full business plan and presentation are available for qualified investors.